NMDA-blocking pharmaceuticals

Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...

Patent

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

A61K 3135

Patent

active

055212158

ABSTRACT:
Pharmaceutical compositions are described for preventing neurotoxicity, crising as active ingredient the stereospecific (+) enantiomer, having (3S,4S) configuration of .DELTA..sup.6 tetrahydrocannabinol type compounds. The compositions are particularly effective in alleviating and even preventing neurotoxicity due to acute injuries to the central nervous system, including mechanical trauma, compromised or reduced blood supply as may occur in cardiac arrest or stroke, or poisonings. They are also effective in the treatment of certain chronic degenerative diseases characterized by gradual neuronal loss.

REFERENCES:
patent: 4133819 (1979-01-01), Johnson
patent: 4179517 (1979-12-01), Mechoulam et al.
patent: 4209520 (1980-06-01), Johnson
patent: 4876276 (1989-10-01), Mechoulam et al.
Mechoulam et al., Tetrahedron Asymmetry 1:315-319 (1990).
Choi, Neuron 1:623-624 (1988).
Kloog et al., Biochemistry 27:843-848 (1988).
Mechoulam et al., Experientia 44:762-764 (1988).
Feigenbaum et al., Pharmacol. Biochem. Behav. 16:235-240 (1982).

LandOfFree

Say what you really think

Search LandOfFree.com for the USA inventors and patents. Rate them and share your experience with other people.

Rating

NMDA-blocking pharmaceuticals does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with NMDA-blocking pharmaceuticals, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and NMDA-blocking pharmaceuticals will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFUS-PAI-O-787287

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.